Propafenone disposition during continuous venovenous hemofiltration

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 957-959

  Seto, Winnie ^a   Trope, Angela E ^c   Gow, Robert M ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c NONE

Author keywords

Hemofiltration; Propafenone

Indexed keywords

5 HYDROXYPROPAFENONE; ANTIARRHYTHMIC AGENT; DRUG METABOLITE; PROPAFENONE;

ARTICLE; CASE REPORT; CHILD; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DRUG DISPOSITION; FEMALE; HEART ARRHYTHMIA; HEART PACING; HEMOFILTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; TACHYCARDIA;

EID: 0032851729     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18359     Document Type: Article

References (10)

1. Ito S, Gow R, Veijee Z, Giesbrecht E, Freedom R, Koren G. Propafenone for supraventricular ectopic tachycardia in infants and children (abstract). Clin Pharmacol Ther 1994;55:176.
2. Burgess E, Duff H. Hemodialysis removal of propafenone. Pharmacotherapy 1989;9:331-3.
3. Hii J, Duff H, Burgess E. Clinical pharmacokinetics of propafenone. Clin Pharmacokinet 1991;21:1-10.
4. Fromm M, Botsch S, Heinkele G, Evers J, Kroemer H. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its Phase I and Phase II metabolites. Eur J Clin Pharmacol 1995;48:279-83.
5. Burgess E, Duff H, Wilkes P. Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol 1989;29:112-3.
6. Poirier J, Joannides R, Geffroy-Josse S, Fillastre J, Etienne I. Propafenone pharmacokinetics in uremic patients treated by peritoneal dialysis. Clin Nephrol 1992;38:231-2.
7. Verjee Z, Giesbrecht E. An HPLC method for the quantitation of propafenone and its metabolites in pediatric samples. In: Sunshine I, ed. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Marcel Dekker, 1992:383-8.
8. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Phannacother 1998;32:362-75.
9. Bauman J, Schoen M, Hoon T. Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles. Clin Pharmacokinet 1991; 20:151-66.
10. Latini R, Maggioni A, Cavalli A. Therapeutic drug monitoring of antiarrhythmic drugs - rationale and current status. Clin Pharmacokinet 1990;18:91-103.